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Introduction: Perinatal depression is well recognised
as a mental health condition but <50% of cases are
identified by healthcare professionals in routine clinical
practice. The Edinburgh Postnatal Depression Scale
(EPDS) is often used to detect symptoms of postnatal
depression in maternity and child services. The
National Institute for Health and Care Excellence (NICE)
recommends 2 ‘ultra-brief’ case-finding questions (the
Whooley questions) to aid identification of depression
during the perinatal period, but this recommendation
was made in the absence of any validation studies in a
perinatal population. Limited research exists on the
acceptability of these depression case-finding
instruments and the cost-effectiveness of routine
screening for perinatal depression.
Methods and analysis: The diagnostic accuracy of the
Whooley questions and the EPDS will be determined
against a reference standard (the Client Interview Schedule
—Revised) during pregnancy (around 20 weeks) and the
early postnatal period (around
3–4 months post partum) in a sample of 379 women.
Further outcome measures will assess a range of
psychological comorbidities, health-related quality of life
and resource utilisation. Women will be followed up
12 months postnatally. The sensitivity, specificity and
predictive values of the Whooley questions and the EPDS
will be calculated against the reference standard at
20 weeks pregnancy and 3–4 months post partum.
Acceptability of the depression case-finding instruments
to women and healthcare professionals will involve
in-depth qualitative interviews. An existing decision
analytic model will be adapted to determine the cost-
effectiveness of routine screening for perinatal depression.
Ethics and dissemination: This study is considered
low risk for participants. Robust protocols will deal with
cases where risk of depression, self-harm or suicide is
identified. The protocol received favourable ethical opinion
from the North East—York Research Ethics Committee
(reference: 11/NE/0022). The study findings will be




Strengths and limitations of this study
▪ This study will fill an important evidence gap
regarding the diagnostic utility of depression
case-finding instruments for the identification of
perinatal depression.
▪ The study findings will be informed by qualitative
interviews conducted with women and healthcare
professionals regarding their acceptability of
depression case-finding instruments adminis-
tered during the perinatal period.
▪ An existing decision analytic model will be
updated with current diagnostic accuracy esti-
mates of two depression case-finding instru-
ments, providing an up-to-date estimate of the
cost-effectiveness of a perinatal depression
screening strategy.
▪ The study findings will inform policy decisions
on the implementation of screening and case-
finding strategies for the identification of peri-
natal depression.
▪ The study spans four National Health Service
(NHS) trusts which may implement differing
policies regarding the identification of and refer-
ral processes for perinatal depression during the
perinatal period.























































































































Depression accounts for the greatest burden of disease
of all mental health problems and is estimated to
become the second largest cause of global disability by
2020.1 It is well recognised that perinatal depression,
that is, depression experienced during pregnancy and/
or the postnatal period (up to 1 year after birth), is an
important category of depression in its own right, with
specific guidance provided on the identification and
clinical management of the condition.2 3
Prevalence rates of perinatal depression vary. Estimates
indicate that ∼7.4–20% of women experience depres-
sion at some stage during pregnancy4–6 with depression
during the postnatal period affecting up to 22% of
women.6 Perinatal depression is associated with a range
of adverse outcomes. Evidence suggests an association
between depression experienced during pregnancy
(prenatal depression) and adverse neonatal outcomes,
poor self-reported health, substance abuse and alcohol
abuse, and poor usage of antenatal care services.5
Postnatal depression has been shown to have a substan-
tial impact on the mother and her partner,7 mother–
baby interactions,8 the family9 and on the longer term
emotional and cognitive development of the baby,10 par-
ticularly when depression occurs in the first year of
life.11
Although perinatal depression is well recognised as a
mental health condition, it often goes undetected; with
healthcare professionals detecting <50% of cases in
routine clinical practice.12 The National Service
Framework (NSF) states that local protocols should be
in place for the management of postnatal depression,13
promoting the use of case-finding or screening strategies
to aid identification of depression during the perinatal
period. This has led to the routine or ad hoc administra-
tion of self-report measures such as the Edinburgh
Postnatal Depression Scale (EPDS).14 Screening or case-
finding strategies such as those advocated by the NSF13
have since come under scrutiny15 16 and have been criti-
cised on a number of factors. Criticisms of the proposed
strategies are based on the ethics of mass screening, con-
cerns regarding the psychometric properties of available
screening or case-finding instruments (such as variations
in diagnostic accuracy estimates and choice of recom-
mended cut-off points for such instruments), the accept-
ability of such screening or case-finding strategies to
patients and healthcare professionals, the paucity of evi-
dence for the cost-effectiveness of screening or case-
finding strategies (particularly the costs associated with
the management of incorrectly identified cases of peri-
natal depression), and the absence of any evidence that
the process of screening leads to effective management
of women with perinatal depression and improved
mother and infant outcomes.16–18
In 2007, the UK National Institute for Health and
Care Excellence (NICE) produced guidelines on ante-
natal and postnatal mental health.2 These set out recom-
mendations for the detection and treatment of mental
health problems during pregnancy and the postnatal
period. As part of these guidelines, NICE endorsed a
case-finding strategy by recommending the use of two
‘ultra-brief’ questions to aid the identification of peri-
natal depression, with the addition of a ‘help’ question
to be asked to those women who answered ‘yes’ to either
of the initial case-finding questions (see box 1); these
questions are often referred to as the ‘Whooley’ ques-
tions.19 However, this NICE recommendation was made
in the absence of any validation studies of these case-
finding (Whooley) questions in a perinatal population.
Instead, NICE called for a validation study to be under-
taken examining the effectiveness of the Whooley ques-
tions against a diagnostic gold standard interview in
women during the first postnatal year.2 Furthermore,
since the commissioning of the current study, NICE
have updated their guidelines in which they continue to
recommend the use of the Whooley questions during
pregnancy and the postnatal period, although they have
removed reference to the use of the additional help
question.3
The Born and Bred in Yorkshire—PeriNatal
Depression Diagnostic Accuracy (BaBY PaNDA) study
therefore aims to close this evidential gap by conducting
a validation study of the Whooley questions against a ref-
erence standard (the Client Interview Schedule—
Revised, CIS-R)20 during pregnancy and the postnatal
period. Given that the EPDS is the measure most com-
monly used to detect symptoms of postnatal depression
in maternity and child services,21 the study will also
include a comparative examination of the diagnostic val-
idity of the EPDS. The authors have previously con-
ducted a systematic review commissioned by the
National Institute for Health Research Health
Technology Assessment Programme (NIHR HTA) of
existing methods to identify postnatal depression in
primary care.18 This revealed a lack of evidence for the
validity of the Whooley questions as an identification
strategy for postnatal depression. This review has since
been updated and found only limited evidence for the
use of the Whooley questions as a case-finding strategy
for postnatal depression.22
The current study builds on pilot work where we have
tested the feasibility of longitudinal validation across the
Box 1 Whooley questions for identifying perinatal depression
recommended by the National Institute for Health and Care
Excellence (NICE)2
1. ‘During the past month, have you often been bothered by
feeling down, depressed or hopeless?’ (‘Yes’/‘no’).
2. ‘During the past month, have you often been bothered by
having little interest or pleasure in doing things?’ (‘Yes’/‘no’).
A third question should be considered if the woman answers ‘yes’
to either of the initial screening questions:
3. ‘Is this something you feel you need or want help with?’ (‘Yes’/
‘yes, but not today’/‘no’).






















































































































perinatal period within the UK National Health Service
(NHS) maternity services. This work produced estimates
of the diagnostic properties of the Whooley questions in
a small but diverse sample of 152 women during preg-
nancy and the early postnatal period.23 The study found
that the Whooley questions had a sensitivity of 100%
(95% CI 77% to 100%) and a specificity of 68% (95%
CI 58% to 76%) during pregnancy, with similar esti-
mates during the early postnatal period (first three post-
natal months). Similar positive likelihood ratios were
found during pregnancy (3.03) and the early postnatal
period (2.73), as was the case for the negative likelihood
ratios (0.041 during pregnancy, 0.042 postnatally). The
BaBY PaNDA study addresses the need to replicate these
results in a larger sample of women representing a
wider geographical population spanning different NHS
trusts.
If case-finding questions are to be used to aid identifi-
cation of perinatal depression in routine clinical practice,
then it is important that they are acceptable to those
women answering the questions and to the healthcare
professionals asking the questions. At the time of commis-
sioning the current study, previous research indicated
that there were limited studies examining the acceptabil-
ity to women and healthcare professionals of depression
case-finding questions, such as the Whooley questions
and the EPDS,18 24 although further research has since
been conducted in this area.25 26 The current validation
study will therefore also include an assessment of the
acceptability to women and healthcare professionals of
such depression case-finding questions and will assess the
potential implications for the care pathway for women
diagnosed with perinatal depression. This important
information will be used alongside the diagnostic esti-
mates of the case-finding questions to inform the imple-
mentation of the NICE-endorsed case-finding strategy.
The current study also aims to investigate additional
and related aspects of perinatal depression, including
the relationship between depression before and after
birth and coexisting psychological symptoms. Policy
recommendations issued by the UK National Screening
Committee (NSC) recognised the need for prospective
epidemiological estimates of perinatal depression and
psychological comorbidity. Research investigating the
natural course of perinatal depression is somewhat
limited. Findings from a large longitudinal community
sample (the Avon Longitudinal Study of Parents and
Children, ALSPAC) suggest higher rates of depressive
symptoms in women (as measured by the EPDS) during
pregnancy than during the postnatal period (up to 8
months).27 Studies which have reported the underdetec-
tion of perinatal depression by healthcare professionals
are largely drawn from cross-sectional studies of post-
natal depression. Further research is needed to deter-
mine the degree to which women with prenatal
depression continue to be symptomatic in the postnatal
period and the proportion of women who are identified
as ‘new cases’ in the postnatal period.
Depression is not always experienced in isolation; epi-
demiological research shows that depression commonly
coexists with other common mental health disorders
such as general anxiety and somatoform symptoms.
Assessments of depression need to recognise and assess
for coexisting psychological symptoms to avoid the risk
of delivering suboptimal treatment strategies. In line
with this, treatment strategies, such as psychosocial inter-
ventions, need to consider the full range of comorbid
psychological symptoms if they are to be effective. NICE
guidance has highlighted the importance of recognising
coexisting psychological comorbidity;28 however, the
issue of psychological comorbidity is not well understood
in perinatal mental health research and the current
study seeks to address this knowledge gap by assessing
women for a range of common mental health disorders.
The current study also seeks to address the concern
that screening for perinatal depression is an inefficient
way of improving the quality of healthcare for pregnant
women and new mothers. The additional health benefit
of implementing screening programmes may be limited
by factors such as the uptake of the screening pro-
gramme and the degree to which additional identified
cases are well managed and respond to treatment. A
major criticism of screening programmes for mental
health disorders is that they identify less severe disorders
and that these identified cases will remit naturally
without the need for any intervention.29 To facilitate an
understanding of the clinical and economic drivers of
the cost-effectiveness of routine screening for postnatal
depression, a decision model has been previously devel-
oped.18 30 A limitation of this model, however, was the
limited availability of primary research on the diagnostic
utility of depression screening questions and the lack of
data on the temporal stability of screening scores and
the natural history of screen-positive scores across the
perinatal period. The BaBY PaNDA study will provide
rich data to help adapt and update this existing decision
model for the perinatal period and will enable us to
produce robust real-world estimates of the cost-
effectiveness of a routine screening and case-finding
strategy for perinatal depression.
This prospective validation study will fill important evi-
dence gaps regarding the diagnostic utility, acceptability
and cost-effectiveness of depression case-finding instru-
ments. It will inform NICE guidance and UK NSC
policy, enabling the NHS to make informed decisions
on the implementation of screening and case-finding
strategies and to plan services on the basis of rigorous
evidence.
Research objectives
The study will combine epidemiological, psychometric,
qualitative and health economic methods to meet a
range of clinically important objectives:
1. Instrument validation: To determine the diagnostic
accuracy of the Whooley depression questions and
the EPDS against a reference standard during






















































































































pregnancy (around 20 weeks gestation) and the early
postnatal period (around 3–4 months after birth).
2. Longitudinal assessment: To assess the temporal stability
of positive and negative screens between pregnancy
and the early postnatal period, and to ascertain
whether there is an optimal time to screen for peri-
natal depression.
3. Assessment of comorbidity: To investigate the coexistence
of depressive symptoms alongside other common
mental health problems.
4. Evaluation of acceptability: To determine the acceptabil-
ity of the Whooley depression questions and the
EPDS to expectant and new mothers and to health-
care professionals, and the potential implications for
the care pathway, during the perinatal period.
5. Estimates of cost-effectiveness: To assess the cost-
effectiveness of the Whooley depression questions
and the EPDS for routine screening for perinatal
depression in maternity services.
METHODS AND ANALYSIS
Study design
The BaBY PaNDA study is a prospective diagnostic accur-
acy study and is embedded within the existing Born and
Bred in Yorkshire (BaBY) pregnancy and birth cohort
study. The BaBY cohort recruits women during preg-
nancy, along with their partners and babies. Data are
collected on maternal and infant health during preg-
nancy, labour and the neonatal period. Information on
the psychological well-being of women and their part-
ners is also obtained during pregnancy and the first
postnatal year. The BaBY cohort study has a target popu-
lation of around 13 500 births per year, with an esti-
mated recruitment rate of >60% of women booked for
delivery at each of four hospital sites (York, Hull,
Harrogate and Scunthorpe & Goole).
The BaBY PaNDA study will determine the diagnostic
accuracy of two depression case-finding instruments (the
index tests)—the Whooley questions and the EPDS—
against a validated assessment of depression, the CIS-R
(the reference standard)20 at two stages—once during
pregnancy (around 20 weeks gestation) and once during
the early postnatal period (around 3–4 months after
birth). A 12-month follow-up will also be conducted.
Concurrent qualitative and cost-effectiveness evaluations
will also be undertaken. The study will take place
between April 2013 and June 2016.
Recruitment
Women will be recruited through the wider BaBY cohort
during a 14-month time period.
Inclusion criteria
Limited inclusion criteria will be applied to ensure a
representative sample of pregnant women are recruited
to the study. Eligible women will be identified from the
population of women taking part in the wider BaBY
cohort study (described above). Pregnant women will be
invited to take part in the study if they have consented
to take part in the wider BaBY cohort and have con-
sented to be contacted again as part of that consent; are
<20 weeks pregnant; are aged 16 years or over; and cur-
rently live in an area covered by one of the four hospital
research sites.
Exclusion criteria
Women will be excluded only if they are non-English
speaking. Women with literacy difficulties will not be
excluded; in such cases, all study information and ques-
tionnaires will be read out to them by the study
researchers. Women who are over 24 weeks gestation at
the time of receipt of a completed consent form will not
be eligible to participate in the study.
Recruitment procedure
Recruitment will take place over a 14-month consecutive
period across each of the four hospital research sites
recruiting to the wider BaBY cohort: York (study coord-
inating site), Hull, Harrogate and Scunthorpe & Goole.
All women who consent to participate in the BaBY
cohort and who meet all the BaBY PaNDA inclusion cri-
teria (including having provided consent to be con-
tacted again) will be invited to take part in the study.
Eligible women will be sent an information pack at
round 15–18 weeks gestation; this will include an invita-
tion letter, a summary information sheet describing the
key aspects of the study, a participant information leaflet
describing the study in detail, a consent form and a
prepaid return envelope. Contact details for the project
team will be provided on the information leaflets,
should women wish to request further information
about the study. Women who wish to take part in the
BaBY PaNDA study will be required to complete the
consent form and return this to the research team.
Women will be contacted by a member of the research
team on receipt of a completed consent form to arrange
the 20-week assessment. Women who do not return a
completed consent form within 2 weeks of receiving the
information pack may be contacted by the research
team to discuss the study and to provide them with an
opportunity to ask further questions about the study.
Information about the BaBY PaNDA study (and the
BaBY cohort) will be sent to all general practitioner
(GP) practices in the recruiting regions and will be dis-
played in locations where pregnant women attend as
part of their maternity care pathway (eg, antenatal
clinics, GP surgeries).
Index tests and reference standard
The study involves validating two separate index tests
against the same reference standard at two separate time
points: 20 weeks pregnancy and 3–4 months postbirth.
The index texts and reference standard will be adminis-
tered within the same session by one researcher, with
the index tests administered before the reference






















































































































standard. For cases where it is not possible to administer
the index tests and the reference standard in the same
session, the reference standard will be administered
within 2 weeks of participants completing the index
tests. The index tests and reference standard will be
administered during face-to-face interviews or over the
telephone and will be conducted at a time and location
according to the woman’s preference (eg, antenatal
clinic, the woman’s home).
Index tests
Whooley questions
Women will be asked the Whooley questions (see box 1)
by a study researcher. A ‘yes’ response to either of ques-
tions 1 or 2 will be considered a positive screen for peri-
natal depression and will require a response to the
‘help’ question (question 3).
The Whooley questions have been previously validated
in primary care populations19 31 and other clinical popu-
lations.32–34 Since the design of the BaBY PaNDA study,
they have also been validated in small perinatal popula-
tions, with sensitivity and specificity estimates in the
range of 46–100% and 65–92%, respectively.23 26 The
Whooley questions were selected as the primary index
test as these questions are recommended by NICE to aid
identification of depression during the perinatal period2
and validation studies for these questions are limited in
a perinatal population.
Edinburgh Postnatal Depression Scale (EPDS)
Women will be asked to self-complete the EPDS;14 this is
a 10-item self-report questionnaire measuring depressive
symptoms over the past 7 days (eg, ‘I have been so
unhappy that I have had difficulty sleeping’, ‘I have felt
sad or miserable’). Each item is scored on a four-point
Likert scale (0–3), with a total score ranging from 0 to
30. The EPDS has a reported sensitivity of 91% and spe-
cificity of 91% when using a cut-off score of ≥13 to
detect major depression in the postnatal period.35 The
EPDS was chosen as one of the index tests as it is a com-
monly used measure to detect symptoms of postnatal
depression in maternity and child services21 and is
widely used in research in perinatal mental health. It
has also been validated for use in pregnancy.36
Reference standard
Clinical interview schedule—revised
Women will be asked to self-complete the computer-
based version of the CIS-R.20 The CIS-R is a fully struc-
tured assessment which assesses 14 areas of symptoms,
including depression, anxiety, sleep, fatigue, panic,
phobias and compulsions/obsessions, and generates
diagnostic categories (including depression severity and
diagnosis), according to the International Classification
of Diseases (ICD-10) criteria.37 Study researchers will be
trained in the use and delivery of the CIS-R.
The CIS-R has been validated in primary care samples
with good reliability and has been used in national
psychiatric morbidity surveys.20 38 It has also been vali-
dated for use over the telephone.39 The CIS-R was
chosen as the reference standard due to its self-report
format.
Blinding of outcome results across index tests and reference
standard
The index tests and reference standard will be adminis-
tered in the same session by one researcher. Within a
session, the level of potential bias is considered minimal
as the EPDS (index test) and CIS-R (reference standard)
are both self-report measures completed on paper
(EPDS) or on a computer (CIS-R) with only minimal
interaction with the researcher. To capture any potential
sources of bias, a ‘participant assessment record sheet’
will be completed by researchers following all sessions
with participants. This will include details of any ques-
tions raised by the participant during completion of the
index tests and reference standard (and any other
outcome measures completed as part of the session)
and any information provided by the participant about
their circumstances (past or current).
Blinding of outcome results of the index tests and ref-
erence standard will be maintained across the two time
points (20 weeks pregnancy and 3–4 months post
partum) with different researchers conducting these ses-
sions for each participant, except in those instances
where it may be more sensitive for the same researcher
to conduct subsequent sessions.
Outcome measures and data collection
Data collection will occur at three time points during
the study:
Stage 1: prenatal (20 weeks pregnancy);
Stage 2: postnatal (3–4-month post partum);
Stage 3: follow-up (12 months post partum).
The main outcome measures will be the two depres-
sion case-finding instruments (as the index tests)—the
Whooley questions and the EPDS. These instruments
will be validated against the CIS-R (as the reference
standard). These three measures will be administered at
stages 1–3.
Further outcome measures will assess a range of psy-
chological comorbidities with a number of self-report
questionnaires administered at stages 1, 2 and 3. These
will assess symptoms of depression (Patient Health
Questionnaire, PHQ-940); anxiety Q3
¶
(GAD-741) and
somatic symptom severity (PHQ-1542). The CIS-R will
also be used to identify other common mental health
disorders, including panic disorder, obsessive-compulsive
disorder and phobias. Health-related quality of life and
health-state utility will be assessed via the SF-1243 and
EQ-5D.44 Resource utilisation will be captured using a
bespoke questionnaire completed at each of the three
stages. Acceptability of the depression case-finding
instruments to women will be assessed with a self-report
acceptability survey originally designed to assess accept-
ability of the EPDS,45 later adapted to include an






















































































































assessment of the Whooley questions,23 and further
adapted for use in the BaBY PaNDA study. The accept-
ability survey will be administered at stages 1 and 2 only.
Acceptability of the depression case-finding instruments
(to both women and healthcare professionals) will also
be determined via in-depth qualitative interviews (see
qualitative interviews section for further detail on the
assessment of acceptability). Minimal biographic and
demographic information will also be obtained at stage
1 only.
Outcome measures will be obtained during
face-to-face interviews at stages 1 and 2. At stage 3, and
for those women unable to attend a face-to-face inter-
view at stage 2, data will be collected by telephone or a
combination of telephone (CIS-R) and post (self-report
questionnaires). Face-to-face interviews will be arranged
for those women who specifically request this method of
data collection at stage 3. Face-to-face interviews will be
conducted at a time and place of the women’s choosing
(eg, antenatal clinic, the women’s home). Women are
advised via the participant information leaflet and
during initial discussions with the study researchers that
each session will last ∼30–40 min.
Sample size
We based the sample size calculation on a previously
developed method for diagnostic accuracy studies.46 For
an expected sensitivity of 95% and a minimal acceptable
lower 95% CI of 80% with 0.95 probability, a total
number of 50 cases of women with depression in the
perinatal period is required. The estimated prevalence
of perinatal depression (prenatal and postnatal) is
20%.6 Attrition between the prenatal and postnatal
stages was estimated at 34%, based on a previous valid-
ation study of the Whooley questions in a perinatal
population.22 Therefore, the sample size needed will be
379 women.
Qualitative interviews
We will conduct a concurrent mixed-methods qualitative
evaluation to determine the acceptability of the
Whooley questions and the EPDS to women (both
during pregnancy and the first postnatal year) and to
healthcare professionals. The interviews will also explore
the extent to which they capture appropriate informa-
tion for effective screening of perinatal depression in
routine perinatal care and the potential implications for
the care pathway of delivering the depression case-
finding instruments in routine care. Interviews will be
conducted by a qualitative researcher.
Participant interviews
Data collection will include both a quantitative survey
(the adapted acceptability survey) to be completed by all
women in the study at stages 1 and 2, and in-depth semi-
structured interviews to be completed with a purposive
subsample of 25–30 women. The interview sampling
framework will aim for maximum variation on the basis
of sociodemographic background, age, parity, positive/
negative screens on the Whooley questions and hospital
research site. Women will participate in a maximum of
three in-depth interviews following completion of the
BaBY PaNDA outcome measures at each of stages 1, 2
and 3 to discuss their views of the depression case-
finding instruments and their associated experience of
the care pathway. Interviews will be conducted on a sub-
sequent and separate occasion to completion of the
BaBY PaNDA outcome measures and will be conducted
at a time and location according to the woman’s prefer-
ence. Interviews will be guided by the use of a semistruc-
tured topic guide based on cognitive interviewing
methodology47 and open-ended probes. Women will
provide their consent to be approached to take part in
in-depth interviews at the point of consenting to the
BaBY PaNDA study. Women who agree to participate in
in-depth interviews will complete a consent form for this
aspect of the study.
Health professional interviews
In-depth semistructured single interviews will be con-
ducted with a purposive sample of six midwives and six
health visitors, to include diversity in age, professional
grade, experience and hospital site. Interviews will
explore health professionals’ views and experience of
using the depression case-finding instruments as part of
routine clinical practice within their NHS trust and their
associated training needs, against descriptions of recom-
mended routine practice and policy from health profes-
sionals in the respective hospital research site. Health
professionals will be provided with an information sheet
about the interviews and will be required to complete a
consent form prior to conducting the interview.
DATA ANALYSIS
Statistical analysis of diagnostic accuracy data
Two-by-two contingency tables will be used to calculate
sensitivity, specificity and predictive values and associated
95% CIs for the Whooley questions and the EPDS
against the reference standard (CIS-R) at stage 1
(20 weeks pregnancy) and stage 2 (3–4 months post-
natal). Receiver operating characteristics (ROC) curves
will be constructed to determine performance character-
istics for the Whooley questions and the EPDS at each
time point. Indeterminate and/or missing results will be
summarised with respect to numbers of women and
reasons (if known). The baseline characteristics of
women with complete data will be compared with those
of women with indeterminate and/or missing data using
descriptive statistics. Predictors of non-response will be
identified using a logistic regression model if there are
sufficient numbers.
Based on the predictive values of the Whooley ques-
tions and the EPDS, we will establish which of the two
time points (20 weeks pregnancy or 3–4 months post-
natal) is better to establish perinatal mental health. The






















































































































temporal stability of participant responses to the
Whooley questions and the EPDS between stages 1 and
2 will be explored using McNemars test. The coexistence
of depressive symptoms alongside other common mental
health problems at stages 1 and 2 will be summarised
descriptively (mean, SD, medium, minimum and
maximum, and frequency and percentages at established
cut points). Full details will be provided in the statistical
analysis plan.
Qualitative analysis
Interviews will be audio-recorded (with participants’
consent) and transcribed verbatim. Transcripts will be
anonymised to ensure confidentiality. Quantitative data
from the acceptability survey will be scored to produce
frequency descriptive data on issues relating to accept-
ability and user preference. Analysis of the qualitative
data from the acceptability survey will be subjected to
thematic content analysis to include coding of data
using constant comparison techniques within the
broader context of the existing literature.
The in-depth interviews will be examined holistically
using phenomenological research methods on a
case-by-case basis to describe women’s and health profes-
sionals’ experience in relation to their own situation and
over time.48–50 Potential sources of response error for
the Whooley questions and the EPDS will be assessed
using the cognitive interview approach. The interview
data will also be used to further examine the findings
from the acceptability survey. The health records of
those women participating in in-depth interviews with a
positive screen on the Whooley questions at stages 1 or 2
may be examined to triangulate their experience of the
depression case-finding instruments and their care
pathway.
Economic analysis
The economic evaluation will be conducted from the
NHS and personal social services perspective and will
include individual-level quality of life data based on the
EQ-5D measure and cost data based on a bespoke
resource-use questionnaire. Data recorded on the time
taken to fully administer the Whooley questions and the
EPDS will also be included. A hypothetical population of
pregnant women managed in primary care will be evalu-
ated using a decision analytic model consisting of two
parts: (1) an identification model which reflects the
diagnostic performance and administration costs of the
Whooley questions and the EPDS as perinatal depres-
sion identification strategies; and (2) a treatment model
which evaluates the health-related costs and outcomes
(expressed as quality-adjusted life years, QALYs) that
may occur following administration of the depression
case-finding instruments. The decision analytic model
will be evaluated for true-positive, false-negative, true-
negative and false-positive diagnosis groups. Using the
diagnostic performance characteristics (sensitivity and
specificity values) of the two depression case-finding
questionnaires, the impact of true and false identifica-
tion of perinatal depression and subsequent treatment
of perinatal depression on costs and QALYs will be eval-
uated over the period of the study.
Probabilistic sensitivity analysis using the Monte Carlo
simulation method51 52 will be undertaken to evaluate
uncertainty in parameter estimates in the decision analytic
model. To evaluate decision uncertainty, the simulation
method will propagate uncertainty in input parameters
through the model. Cost-effectiveness plane will be used to
present the joint distribution of incremental costs and
QALYs. Cost-effectiveness acceptability curves will repre-
sent the probability that the Whooley questions are cost-
effective compared with the EPDS as a depression case-
finding instrument for a range of willingness to pay thresh-
olds that a UK decision-maker may consider.53
The decision model will be developed with reference
to NICE guidelines for antenatal and postnatal mental
health2 3 to reflect recommended clinical practice and
to ensure that the decision model is realistic and rele-
vant to clinical context.
STUDY STATUS
Recruitment of participants is completed. The first par-
ticipant was enrolled in August 2013. The last partici-
pant will complete follow-up (stage 3) in January 2016.
ETHICS AND DISSEMINATION
Ethical issues
Ethical and safety considerations
As this study does not involve providing any form of
intervention, we do not anticipate any major ethical con-
cerns and consider this study low risk for participants.
However, we acknowledge that some women may be vul-
nerable during pregnancy and the postnatal period and
may feel anxious about the identification of risk of
depressive symptoms. There may also be ethical issues
relating to the identification of possible cases of self-
harm and/or suicide. Such issues may arise following
completion of study outcomes and/or participation in
qualitative interviews. Members of the research team
have experience of conducting mental health studies
and are well placed to deal with such ethical issues.
Further, clinical members of the research team will be
available to discuss any issues or concerns with research-
ers and/or the participant, if felt appropriate or
requested. We will follow good clinical practice in moni-
toring risk for self-harm/suicide during researcher
encounters with all participants. Robust protocols will be
in place to deal with cases where risk of depression, self-
harm or suicide is identified or expressed; this may
involve contacting the participant’s GP where necessary,
with the participant’s consent.
Anticipated risks and benefits
This study is considered low risk for participants.
Participants will continue to receive their usual standard






















































































































of maternity care, and participation in this study will not
affect the standard of care they receive from their GP,
midwife or health visitor. No treatment will be withheld
from participants by their taking part in the study.
Information about known risks and possible benefits of
taking part in the study will be provided in the participant
information sheet. Participants will be informed if new
information comes to light which may affect their willing-
ness to participate in the study. The participant informa-
tion sheet advises potential participants that they may
wish to discuss participation in the study with their GP.
Obtaining informed consent
Eligible participants will receive an information pack
about the study by post. This will contain an invitation
letter, a summary information leaflet, a detailed partici-
pant information sheet and a consent form. The partici-
pant information sheet will provide contact details of
the research team should participants wish to request
further information about the study or ask any questions
before providing their written consent. Researchers will
discuss the study with participants and answer any ques-
tions during first contact with the participant following
receipt of written informed consent.
Retention of study documentation
Study data will be stored in accordance with the
Department of Health Sciences Data Security Policy at
the University of York. Paper records will be stored in
secure facilities, and all electronic records will be stored
on a password-protected server within the Department
of Health Sciences at the University of York. Personal
identifiable paper records will be stored in a separate
location from anonymised data paper records. All per-
sonal information will be destroyed at the end of the
study. Anonymised data will be stored for a minimum of
20 years after the final study analysis.
Dissemination plan
We will publish the findings of this study to include (as a
minimum) the diagnostic performance of the Whooley
depression questions and the EPDS during pregnancy
and the early postnatal period, as well as the findings
from the qualitative interviews with participants and
health professionals and results of the cost-effectiveness
analysis. Findings will be published in peer-reviewed
journals and professional journals to ensure accessibility
to health researchers and clinicians. Study findings will
be published using the Standards for Reporting
Diagnostic Accuracy studies (STARD) guidelines.54 55 We
will present our findings at national conferences on
perinatal depression, enabling the effective dissemin-
ation of our results to a wide target audience, to include
midwives, health visitors, GPs and mental health profes-
sionals. We will also issue a press release to ensure cover-
age of our findings in the wider media. We will produce
a short summary of the results for dissemination to all
study participants as well as other relevant patient and
other interest groups.
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